Ceribell, Inc. launches FDA-cleared device for bedside diagnosis and delirium monitoring

Ceribell, Inc. launches FDA-cleared device for bedside diagnosis and delirium monitoring
Ceribell, Inc. launches brain monitor

Ceribell, Inc. has introduced the first and only FDA-cleared device designed for bedside diagnosis of electrographic status epilepticus and monitoring of delirium in adults.

This new bedside monitor aims to assist clinicians in providing rapid, accurate neurological assessments for critical care patients. The device is presented as an innovation that unifies two vital brain function applications into a single platform, potentially enhancing clinical workflow and patient outcomes. The announcement was made at #ADS2026, signaling the company's commitment to advancing neurological monitoring technology.

Ceribell has previously called for rapid EEG adoption to detect silent seizures in high-acuity patients and prevent irreversible harm, according to an earlier report on urgent seizure detection. The company continues to focus on bedside technologies that support neurological assessments in critical care. This development follows its prior initiatives aimed at addressing gaps in seizure identification.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.